Mayukh Sukhatme Sells 144,756 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the transaction, the insider directly owned 18,630,739 shares in the company, valued at approximately $679,649,358.72. This represents a 0.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The shares were sold at an average price of $37.17, for a total value of $6,426,655.83.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The shares were sold at an average price of $37.30, for a total value of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $36.30 on Friday. Roivant Sciences Ltd. has a 1 year low of $11.60 and a 1 year high of $37.97. The firm has a market cap of $26.22 billion, a PE ratio of -68.49 and a beta of 1.12. The stock has a fifty day moving average price of $34.61 and a 200-day moving average price of $30.43.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, equities analysts anticipate that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. lifted its holdings in Roivant Sciences by 15.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after purchasing an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp raised its position in shares of Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after purchasing an additional 1,181 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on ROIV. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Guggenheim lifted their price target on shares of Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday. Finally, Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.